Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deucravacitinib versus placebo in biologic-naive active psoriatic arthritis
2023-506256-25-00Phase 3Authorised
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial in psoriatic arthritis (PsA) comparing Deucravacitinib with Placebo comparator (2 arms). Primary endpoint: ACR20 response at Week 16. Planned start Oct 2021; status: authorised.
02
Drugs
deucravacitinib
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2023-506256-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506256-25-00.